Literature DB >> 16960470

Is history of depression a contraindication to treatment with tetrabenazine?

Christopher Kenney1, Christine Hunter, Nicte Mejia, Joseph Jankovic.   

Abstract

OBJECTIVE: To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom.
METHODS: We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Charts were screened for the preexistence, development, or exacerbation of depression during the course of treatment.
RESULTS: The most common adverse events related to TBZ were somnolence (27.4%), depression (15.1%), parkinsonism (11.8%), and akathisia (8.9%); 78 patients (15.1%) experienced depression for the first time or an exacerbation of existing depression. Of those patients with no history of depression, 28 (11.4%) of 246 were newly diagnosed with depression. Patients with a documented history of depression experienced a significantly higher rate of worsening in 50 (18.4%) of 272 cases (P = 0.03). However, patients with a history of depression experienced more improvement of their hyperkinesia compared to those without a history of depression (P < 0.01).
CONCLUSIONS: Depression, an adverse event of TBZ, is more likely to occur or worsen in patients with a preexisting history of depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960470     DOI: 10.1097/01.WNF.0000228369.25593.35

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  14 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

3.  Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.

Authors:  Benjamin Ray Miller; Ilya Bezprozvanny
Journal:  Future Neurol       Date:  2010-09

4.  Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study.

Authors:  Rita Miguel; Marcelo D Mendonça; Raquel Barbosa; Filipa Ladeira; Tânia Lampreia; José Vale; Paulo Bugalho
Journal:  Ther Adv Neurol Disord       Date:  2016-11-21       Impact factor: 6.570

5.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

Review 6.  Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 7.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 8.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 9.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease.

Authors:  Jean-Marc Burgunder; Mark Guttman; Susan Perlman; Nathan Goodman; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.